In addition, complementary treatments to block immune suppression in the tumor microenvironment, including depletion of regulatory T cells, inhibition of suppressor enzyme (e.g., TGFβ, IDO) function or blocking metabolic reprogramming, is mandatory to realize the full capacity of therapeutic cancer vaccines [2,44,45]. The gene discussed is TGFB1; the disease is neoplasm.